Innate lymphoid cell (ILC) subsets are enriched in the skin of patients with hidradenitis suppurativa

PLoS One. 2023 Feb 13;18(2):e0281688. doi: 10.1371/journal.pone.0281688. eCollection 2023.

Abstract

Hidradenitis suppurativa (HS) is a chronic relapsing inflammatory skin disease manifested as painful inflamed lesions including deep-seated nodules, abscesses and sinus tracts. The exact aetiology of HS is unclear. Recent evidence suggests that immune dysregulation plays a crucial role in pathogenesis and disease progression. Innate lymphoid cells (ILC) are a recently identified immune cell subset involved in mediating immunity, however their role in HS has not yet been investigated. Three distinct subsets of ILC- ILC1, ILC2 and ILC3 have been described, and these are involved in skin tissue homeostasis and pathologic inflammation associated with autoimmunity and allergic diseases. In this study, we analysed by multiparameter flow cytometry the frequencies of ILC subsets in skin and peripheral blood mononuclear cells (PBMC) of HS patients and compared these to healthy control subjects and psoriasis patients. The absolute numbers of total ILC and subsets thereof were significantly reduced in the blood of HS patients relative to healthy controls. However, when patients were stratified according to treatment, this reduction was no longer observed in patients undergoing anti-TNF treatment. In HS lesional skin the absolute numbers of ILC were significantly increased relative to control skin. Furthermore, the frequencies of total ILC as well as ILC2 and ILC3 were significantly higher in non-lesional than lesional HS skin. This study analysed for the first time the presence of ILC subsets in the blood and skin of HS patients. Our findings suggest that ILC may participate in HS pathogenesis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Hidradenitis Suppurativa*
  • Humans
  • Immunity, Innate*
  • Inflammation
  • Leukocytes, Mononuclear
  • Lymphocytes
  • Tumor Necrosis Factor Inhibitors

Substances

  • Tumor Necrosis Factor Inhibitors

Grants and funding

This study was supported by a grant (008/SG/17) from The British Skin Foundation (https://www.britishskinfoundation.org.uk) and by a grant from The City of Dublin Skin and Cancer Hospital Charity (https://www.cdschc.ie/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.